Back to News
Market Impact: 0.25
Kamada Confirms KedRAB Supply As U.S. Rabies Exposures Increase
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
Kamada confirmed it has sufficient KedRAB inventory and manufacturing capacity to meet increased U.S. demand following the CDC's September 10, 2026 health advisory. The update indicates supply readiness for the rabies immune globulin product and could support near-term demand, although no sales or financial guidance was provided.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
KMDA0.58
More News
- Binance seeks to shore up confidence after record $6.3 billion heist
- Why is Alstom stock down 27% today?
- Amgen (AMGN) Bets on MariTide to Crack $120 Billion Obesity Market
- Alstom shares sink 28% after outlook cut on Coradia Max execution issues
- Kosmos Energy stock sinks on third quarter earnings, revenue miss
- NUBURU Completes Tekne Acquisition, Adding a $93 Million Defense & Dual-Use Program Portfolio and Advancing Expansion Across NATO and Allied Markets